Selected article for: "epithelial cell and RNA seq"
Author: Arjmand, Sareh; Hosseinkhan, Nazanin
Title: Identification of potential coagulation pathway abnormalities in SARS-Cov-2 infection; insights from bioinformatics analysis
  • Cord-id: 1gr2a9c7
  • Document date: 2020_12_7
    • ID: 1gr2a9c7
    Snippet: Abnormal coagulation parameters have been explored in a significant number of severe COVID-19 patients, linked to poor prognosis and increased risk of organ failure. Here, to uncover the potential abnormalities in coagulation pathways, we analyzed the RNA-seq data (GEO147507) obtained from the treatment of three pulmonary epithelial cell lines with SARS-CoV-2. The significant differentially expressed genes (DEGs) were subjected to Enrichr database for KEGG pathway enrichment analysis and gene on
    Document: Abnormal coagulation parameters have been explored in a significant number of severe COVID-19 patients, linked to poor prognosis and increased risk of organ failure. Here, to uncover the potential abnormalities in coagulation pathways, we analyzed the RNA-seq data (GEO147507) obtained from the treatment of three pulmonary epithelial cell lines with SARS-CoV-2. The significant differentially expressed genes (DEGs) were subjected to Enrichr database for KEGG pathway enrichment analysis and gene ontology (GO) functional annotation. The STRING database was used to generate PPI networks for identified DEGs. We found three upregulated procoagulant genes (SERPINE1, SERPINA5, and SERPINB2) belong to the serine protease inhibitor (serpin) superfamily that inhibit tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) in the fibrinolysis process. In conclusion, we suggest the fibrinolysis process, especially the blockage of t-PA and u-PA inhibitors, a potential target for more study in treating coagulopathy in severe COVID-19 cases.

    Search related documents:
    Co phrase search for related documents
    • active form and acute respiratory distress syndrome: 1
    • active form and liver damage: 1
    • active form and liver kidney: 1
    • active form and lung epithelium: 1
    • active form and lung inflammation: 1
    • active form convert and acute respiratory: 1
    • active protein and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • active protein and acute respiratory distress syndrome: 1
    • active protein and lung alveolar: 1, 2
    • active protein and lung injury: 1
    • liver damage and lung alveolar: 1, 2
    • liver damage and lung epithelium: 1
    • liver damage and lung inflammation: 1
    • liver damage and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • liver kidney and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • liver kidney and lung epithelium: 1, 2, 3, 4, 5, 6, 7, 8
    • liver kidney and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
    • liver kidney and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • liver kidney and lung postmortem examination: 1